Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort studyNarendranath Epperla, Reem Karmali, Jane N. Winter et al.|Journal of Hematology & Oncology|2023Cited by 52
Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHLJoanna Zurko, Reem Karmali, Imran Nizamuddin et al.|Blood Advances|2022Cited by 50
Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective studyDavid Qualls, Gilles Salles, Nicholas Lambert et al.|Blood|2023Cited by 47
Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective StudyDavid Qualls, Connie Lee Batlevi, Michael J. Buege et al.|Blood|2022Cited by 20
Loncastuximab in High-Risk and Heavily-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real World Analysis from 21 US CentersEmily C. Ayers, Narendranath Epperla, Viktoriya Zelikson et al.|Blood|2023Cited by 10